Abstract
The DNA damage response (DDR) encompasses the cellular response to DNA double-stranded breaks (DSBs), and includes recognition of the DSB, recruitment of numerous factors to the DNA damage site, initiation of signaling cascades, chromatin remodeling, cell-cycle checkpoint activation, and repair of the DSB. Key drivers of the DDR are multiple members of the phosphatidylinositol 3-kinase-related kinase family, including ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3-related (ATR), and the DNA-dependent protein kinase catalytic subunit (DNA-PKcs). ATM and ATR modulate multiple portions of the DDR, but DNA-PKcs is believed to primarily function in the DSB repair pathway, non-homologous end joining. Utilizing a human cell line in which the kinase domain of DNA-PKcs is inactivated, we show here that DNA-PKcs kinase activity is required for the cellular response to DSBs immediately after their induction. Specifically, DNA-PKcs kinase activity initiates phosphorylation of the chromatin factors H2AX and KAP1 following ionizing radiation exposure and drives local chromatin decondensation near the DSB site. Furthermore, loss of DNA-PKcs kinase activity results in a marked decrease in the recruitment of numerous members of the DDR machinery to DSBs. Collectively, these results provide clear evidence that DNA-PKcs activity is pivotal for the initiation of the DDR.
Original language | English (US) |
---|---|
Pages (from-to) | 9467-9479 |
Number of pages | 13 |
Journal | Nucleic acids research |
Volume | 47 |
Issue number | 18 |
DOIs | |
State | Published - Oct 10 2019 |
Bibliographical note
Funding Information:National Institutes of Health [CA092584, CA162804, and GM047251 to A.J.D.; CA190492, GM088351 to E.A.H.]. Funding for open access charge: National Institutes of Health [CA092584, CA162804]. Conflict of interest statement. A.J.D., H.L., J.S. and P.J.B declare no con?ict of interest. E.A.H. belongs to the scientifc advisory boards of Horizon Discovery and Intellia Therapeutics.
Funding Information:
National Institutes of Health [CA092584, CA162804, and GM047251 to A.J.D.; CA190492, GM088351 to E.A.H.]. Funding for open access charge: National Institutes of Health [CA092584, CA162804]. Conflict of interest statement. A.J.D., H.L., J.S. and P.J.B declare no conflict of interest. E.A.H. belongs to the scientific advisory boards of Horizon Discovery and Intellia Therapeutics.
Publisher Copyright:
© 2019 The Author(s).